We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Pathogen Molecular Diagnostics Evaluated for Routine Use

By LabMedica International staff writers
Posted on 24 Jun 2013
Molecular diagnosis of microbial etiologies using a universal polymerase chain reaction (PCR) and sequencing test has been evaluated in the daily routine of a diagnostic laboratory. More...


The identification of bacterial and fungal pathogens using the test has been analyzed in a privately operated diagnostics laboratory, including the interpretation of the data, and the experience in performing the PCR test.

Medical laboratory scientists from the Dr. Constance Brunner Laboratory (Konstanz, Germany) examined 96 specimens originating from 66 patients under suspect of infectious endocarditis, infections of joints, encephalitis/meningitis, systemic infections, and infections of unknown origin. Samples comprised cultured and noncultured blood, synovial fluid, synovial tissue, heart valves, pacemakers, spinal tissue, cerebrospinal fluid, and swabs.

The samples were analyzed by the SepsiTest (Molzym; Bremen, Germany) and compared to culture results. Primers specific for 16S ribosomal ribonucleic (rRNA) eubacterial sequences and primers, predominantly specific for Gram-positive microorganisms (GP) were used for amplification. A third PCR was included by routine, covering predominantly the Gram-negative bacteria (GN). Pan-fungal or 18S rRNA gene-specific PCR was done on explicit request only. The 16S primers used are included in the SepsiTest kit, but GP and GN primers were ordered separately from Molzym.

The SepsiTest PCR and culture were concordant in 26 negative and 8 positive cases. A group of 25 patients was culture-negative, but PCR-positive. In at least 14 of these, common and/or rare etiologies were identified, while for 4 patients the results of 16S PCR could not be unequivocally linked with the underlying disease. Another large group of 29 patients’ samples was discordant in PCR and culture results, including 25 PCR-positive, but culture-negative, and 4 were PCR-positive and culture-positive, but with the identification result being discordant from that obtained by PCR.

The authors concluded that despite the limitations imposed on its use such as costs, false positives due to environmental contamination, SepsiTest turned out to be a tool appropriate for the diagnosis of pathogens in the clinical routine. Nevertheless, as the results show, the test cannot replace but may rather complement culture diagnosis, especially as a tool for ultima-ratio analysis. The study was published on June 7, 2013, in the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

Dr. Constance Brunner Laboratory
Molzym



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
New
Portable POCT Blood Gas Analyzer
BD100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.